Compare GLNG & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLNG | INAB |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 15.6M |
| IPO Year | 2002 | 2020 |
| Metric | GLNG | INAB |
|---|---|---|
| Price | $49.80 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $50.63 | $6.00 |
| AVG Volume (30 Days) | ★ 1.6M | 60.3K |
| Earning Date | 11-21-2023 | 05-11-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.14 | N/A |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | $80.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.02 | $1.17 |
| 52 Week High | $57.79 | $4.20 |
| Indicator | GLNG | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 32.62 | 68.74 |
| Support Level | $38.79 | $1.52 |
| Resistance Level | $57.30 | $2.14 |
| Average True Range (ATR) | 1.65 | 0.10 |
| MACD | -0.91 | 0.03 |
| Stochastic Oscillator | 13.98 | 95.85 |
Golar LNG Ltd designs, converts, owns, and operates marine infrastructure for the liquefaction of natural gas and provides floating liquefied natural gas (FLNG) services. It offers solutions for gas resource holders to develop and utilize gas reserves, including stranded, associated, flared, or underutilized resources. The company's reportable segments are: i) FLNG: includes the operations of FLNG vessels and projects, and ii) Corporate and other: includes legacy shipping segment activities, vessel management, floating storage and regasification unit services for third parties. The majority of the company's revenue is derived from the FLNG segment. Geographically, it generates the maximum revenue from Cameroon.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.